CLL/SLL diagnosed in an adolescent

Pediatric Blood and Cancer

Volumn 61, Issue 6, 2014, Pages 1107-1110

  Luskin, Marlise ^a   Wertheim, Gerald ^a,b   Morrissette, Jennifer ^a   Daber, Robert ^a   Biegel, Jaclyn ^b   Wilmoth, Donna ^b   Kersun, Leslie ^b   King, Rebecca ^a,b   Paessler, Michele ^a,b   Simon, Cara ^b   Aplenc, Richard ^b   Loren, Alison ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Cancer genetics; Non Hodgkin lymphoma; Rare tumors

Indexed keywords

ATM PROTEIN;

ADOLESCENT; ARTICLE; BLOOD CELL COUNT; CANCER THERAPY; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; DNA SEQUENCE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHADENOPATHY; LYMPHOCYTOMA; MALE; MONONUCLEAR CELL; PRACTICE GUIDELINE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

CANCER GENETICS; NON-HODGKIN LYMPHOMA; RARE TUMORS;

ADOLESCENT; AGE FACTORS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 8; DIAGNOSTIC IMAGING; GENE DOSAGE; GENES, MYC; HUMANS; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPH NODES; MALE; SEQUENCE DELETION; TUMOR MARKERS, BIOLOGICAL;

EID: 84901720373     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24884     Document Type: Article

References (20)

1. Howlader N, Noone AM, Krapcho M, et al., editors. SEER cancer statistics review, 1975-2010. National Cancer Institute. Bethesda, MD: National Cancer Institute; 2013. http://seer.cancer.gov/csr/1975_2010/
2. Döhner H, Stilgenbauer S, James MR, et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997; 89:2516-2522.
3. Brown JR, Hanna M, Tesar B, et al. Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. Clin Cancer Res 2012; 18:3791-3802.
4. Sperka T, Wang J, Rudolph KL. DNA damage checkpoints in stem cells, ageing and cancer. Nat Rev Mol Cell Biol 2012; 13:579-590.
5. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455:1069-1075.
6. Rossi D, Gaidano G. ATM and chronic lymphocytic leukemia: Mutations, and not only deletions, matter. Haematologica 2012; 97:5-8.
7. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343:1910-1916.
8. Austen B, Skowronska A, Baker C, et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol 2007; 25:5448-5457.
9. Skowronska A, Parker A, Ahmed G, et al. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. J Clin Oncol 2012; 30:4524-4532.
10. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23:4079-4088.
11. Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007; 109:405-411.
12. Nivison-Smith I, Simpson JM, Dodds AJ, et al. Relative survival of long-term hematopoietic cell transplant recipients approaches general population rates. Biol Blood Marrow Transplant 2009; 15:1323-1330.
13. Pond GR, Lipton JH, Messner HA. Long-term survival after blood and marrow transplantation: Comparison with an age- and gender-matched normative population. Biol Blood Marrow Transplant 2006; 12:422-429.
14. Schetelig J, van Biezen A, Brand R, et al. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: A retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol 2008; 26:5094-5100.
15. Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood 2012; 120:4684-4691.
16. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369:32-42.
17. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725-733.
18. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3:95-73.
19. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012; 119:2709-2720.
20. Brentjens RJ, Rivière I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011; 118:4817-4828.